RPG Life Sciences Limited — Earnings Release 2023

Apr 28, 2023

==> picture [439 x 29] intentionally omitted <==

==> picture [439 x 28] intentionally omitted <==

==> picture [439 x 10] intentionally omitted <==

April 28, 2023

The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limited Floor 25, P.J. Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No. C-1, G- Block, Mumbai 400 001 Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2023.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited Rajesh Shirambekar Head – Legal & Company Secretary

==> picture [58 x 55] intentionally omitted <==

Encl.: as above

==> picture [74 x 34] intentionally omitted <==

==> picture [156 x 61] intentionally omitted <==

Q4 FY23 Revenue from operations grew by 14% and PBT grew by 26% Y-o-Y. Full year FY23 Revenue from operations grew by 17% and PBT grew by 25% with EBITDA margin expanding from 20.3% to 21.0% Y-o-Y.

Mumbai, 28 April, 2023 : RPG Life Sciences Limited has announced its financial results for the fourth quarter and year ended March 31, 2023.

ended March 31, 2023.
Q4 FY23 Highlights	Y-o-Y Revenue from operationsY-o-Y PBT
	Rs 118.49 crores – up from Rs 103.80 crores Rs 13.81 crores – up from Rs 10.93 crores
Full year FY23 Highlights	Rs 512.81 crores – up from Rs 440.16 crores	Rs 91.68 crores – up from Rs 73.17 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 26% Y-o-Y for Q4 FY23, maintaining the upward trajectory in EBITDA margins, which improved from 14.2% to 15.0% Y- o-Y. Revenue from operations at Rs 118.49 crores registered a growth of 14% Y-o-Y for Q4 FY23.

For full year FY23 too, the company posted a jump in PBT by 25% Y-o-Y and recorded EBITDA margin expansion from 20.3% to 21.0% Y-o-Y. Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q4 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong result despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by a healthy 14% and 26% respectively Y-o-Y. EBITDA margins’ consistent upward trajectory has continued for the last 5 years, growing from 10.4% (FY19) to 15.9% (FY20) to 18.2% (FY21) to 20.3% (FY22) to 21.0% (FY23). The Company continues to remain debt-free with the highestever net cashflow generated from operations in full year FY23.

Domestic Formulations business, the biggest contributor to the company’s business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments.

International Formulations business has also shown robust growth, while emerging as another growth driver for the Company, registering healthy growth in both sales and profits. Company is investing in plant upgradation and capacity expansion in both plants as well as working on building healthy product pipeline to accelerate exports. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Svati Maddur Senior Manager – Corporate Brand and Group Communications +91 9920887227 | svati@rpg.in

==> picture [130 x 27] intentionally omitted <==